8-K: Relmada Therapeutics Appoints Renowned Urology Expert Dr. Raj S. Pruthi as Chief Medical Officer to Lead Bladder Cancer Program

Relmada Therapeutics, Inc. announced the appointment of Dr. Raj S. Pruthi as Chief Medical Officer-Urology to spearhead the development of its lead non-muscle invasive bladder cancer (NMIBC) program, NDV-01, with a Phase 3 trial expected to commence in H1 2026.

Summary

• Relmada Therapeutics, Inc. appointed Raj S. Pruthi, MD as Chief Medical Officer-Urology on June 17, 2025.
• Dr. Pruthi will lead the development of NDV-01, the company's lead program for non-muscle invasive bladder cancer (NMIBC).
• Positive initial Phase 2 data for NDV-01 was presented at the American Urology Association 2025 Annual Meeting on April 28, 2025.
• A Phase 3 trial for NDV-01 is expected to begin in the first half of 2026 (H1 2026).
• NDV-01 is a sustained-release, intravesical formulation of gemcitabine and docetaxel (GEM/DOCE), designed for in-office administration in less than 10 minutes.
• The NMIBC market opportunity is significant, with over 600,000 prevalent cases in the U.S. and high recurrence rates (50-75% over 7 years).
• NDV-01 is protected by patents through 2038.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the strategic appointment of a highly qualified Chief Medical Officer for a key program, the positive Phase 2 data, and the clear timeline for advancing to a Phase 3 trial for a drug targeting a significant unmet medical need. The patent protection through 2038 also adds to the positive outlook.

Positives

• Appointment of a highly experienced Chief Medical Officer-Urology, Dr. Raj S. Pruthi, with over 25 years in urologic oncology, clinical trials, and robotic surgery.
• Dr. Pruthi's expertise includes contributing to AUA practice guidelines for NMIBC and designing global clinical studies for bladder cancer.
• Positive initial Phase 2 data for NDV-01, showing impressive response rates and favorable tolerability with a simple, ready-to-use administration.
• NDV-01's unique sustained-release formulation of gemcitabine/docetaxel (GEM/DOCE) enhances local exposure while minimizing systemic toxicity.
• Significant market opportunity for NMIBC, with over 600,000 prevalent cases in the U.S. and high recurrence rates, indicating a strong unmet need.
• NDV-01 is protected by patents through 2038, providing long-term market exclusivity.
• The company is advancing two lead candidates, NDV-01 and sepranolone, through mid-stage clinical development.

Negatives

• The company is a clinical-stage biotechnology company, meaning its lead programs are still in development and not yet generating commercial revenue.
• Current treatments for NMIBC are described as complex to administer and burdensome for patients, highlighting challenges in the existing treatment landscape.

Risks

• Potential for Relmada's product candidates to not progress as expected.
• Potential for Phase 2 NDV-01 data to not continue to deliver positive results supporting further development.
• Potential for clinical trials to fail to deliver statistically and/or clinically significant evidence of efficacy and/or safety.
• Risk that top-line results may not accurately reflect the complete results of the trial.
• Failure of planned or ongoing preclinical and clinical studies to demonstrate expected results.
• Potential failure to secure FDA agreement on the regulatory path for sepranolone and NDV-01.
• Risk that future sepranolone or NDV-01 clinical results will not be acceptable to the FDA.
• Failure to secure adequate sepranolone or NDV-01 drug supply.

Future Outlook

Relmada Therapeutics expects to initiate the Phase 3 trial for its lead non-muscle invasive bladder cancer (NMIBC) program, NDV-01, in the first half of 2026. The company believes NDV-01 has the potential to become a class-leading therapy for NMIBC, serving as a frontline or salvage therapy across multiple NMIBC subtypes.

Management Comments

• "We are very pleased to welcome Raj to Relmada. As we prepare to begin registrational studies, we believe Rajs extensive clinical experience will play a vital role in the NDV-01 programs success." Sergio Traversa, CEO, Relmada.
• "Additionally, we have a strong belief that Rajs first-hand understanding of approved bladder cancer therapies and the clinical evidence that is required for widespread physician adoption of new therapies will be a significant asset for Relmada." Sergio Traversa, CEO, Relmada.
• "Advancing innovative, bladder-sparing treatments for bladder cancer has been the focus of my career. I joined Relmada because I believe NDV-01 has unique potential to become a class-leading therapy for the treatment of NMIBC." Dr. Raj S. Pruthi, CMO, Relmada.
• "I am enthusiastic about working with my colleagues at Relmada to achieve our goal of initiating the Phase 3 trial in H1 2026 and bringing NDV-01 to patients with NMIBC as soon as possible." Dr. Raj S. Pruthi, CMO, Relmada.

Industry Context

The appointment of a specialized Chief Medical Officer for urology highlights Relmada's strategic focus on advancing its lead non-muscle invasive bladder cancer (NMIBC) program, NDV-01, in a market characterized by high recurrence rates and limited, burdensome treatment options. This move positions Relmada to potentially address a significant unmet medical need within the oncology sector, aligning with broader industry efforts to develop more effective and patient-friendly cancer therapies.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results for direct assessment against global benchmarks.
• However, it notes that current NMIBC treatments are complex and burdensome, implying NDV-01's simple, ready-to-use administration and sustained-release formulation could offer a competitive advantage over existing therapies like those involving gemcitabine/docetaxel administered without such a delivery system.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strengthening of management team, advancement of a key clinical program (NDV-01) towards Phase 3, and potential for future revenue generation from a significant market.
• Patients (NMIBC): Potential for a new, less burdensome, and effective treatment option (NDV-01) if clinical trials are successful.
• Employees: Potential for increased stability and growth as the company progresses its pipeline.
• Medical Community: Introduction of a highly experienced physician-scientist to lead a promising bladder cancer program, potentially contributing to new treatment guidelines and practices.

Next Steps

• Initiate Phase 3 trial for NDV-01 in H1 2026.
• Continue development of NDV-01 to bring it to NMIBC patients.
• Further development of sepranolone.

Key Dates

Keywords

Relmada Therapeutics, RLMD, Biotechnology, Clinical-stage, NDV-01, Non-muscle invasive bladder cancer, NMIBC, Urology, Chief Medical Officer, Raj S. Pruthi, Oncology, Drug development, Phase 3 trial, Gemcitabine, Docetaxel, SEC filing, 8-K